



Standard Specification for Medical-Grade Ultra-High Molecular Weight Polyethylene Yarns¹

This standard is issued under the fixed designation F2848; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This specification covers ultra-high molecular weight polyethylene (UHMWPE) yarns intended for use in medical devices or components of medical devices, such as sutures and ligament fixations.

1.2 This standard is intended to describe the required properties and the procedures to be followed for testing UHMWPE yarns as raw materials for medical devices. This specification does not purport to address the testing that is needed for medical devices or components of medical devices that are fabricated from the raw materials specified herein.

1.3 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.4 The following precautionary caveat pertains only to the test method portion, Section 6, of this specification: *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.*

2. Referenced Documents

2.1 ASTM Standards:²

[D792 Test Methods for Density and Specific Gravity \(Relative Density\) of Plastics by Displacement](#)

[D885 Test Methods for Tire Cords, Tire Cord Fabrics, and Industrial Filament Yarns Made from Manufactured Organic-Base Fibers](#)

[D1907 Test Method for Linear Density of Yarn \(Yarn Number\) by the Skein Method](#)

[D2256 Test Method for Tensile Properties of Yarns by the](#)

Single-Strand Method

[F648 Specification for Ultra-High-Molecular-Weight Polyethylene Powder and Fabricated Form for Surgical Implants](#)

[F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices](#)

2.2 ISO Standards:³

[ISO 1628-3 Plastics—Determination of the Viscosity of Polymers in Dilute Solution Using Capillary Viscometers—Part 3: Polyethylenes and Polypropylenes](#)

[ISO 2062 Textiles—Yarns from Packages—Determination of Single-end Breaking Force and Elongation at Break](#)

[ISO 10993 Biological Evaluation of Medical Devices](#)

2.3 Other Documents:

[ICH Q3C\(R3\) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Quality Guideline: Impurities: Residual Solvents⁴](#)

3. Terminology

3.1 Definitions of Terms Specific to This Standard:

3.1.1 *UHMWPE filament*—molecularly oriented highly crystalline fiber spun from virgin UHMWPE polymer powder.

3.1.2 *UHMWPE yarn*—a continuous strand of more than one UHMWPE filaments in a form suitable for operations such as weaving, knitting, etc., prior to packaging and sterilization.

3.1.3 *linear density*—mass per length, expressed in dtex (mass in grams per 10 000 metres).

3.1.3.1 *Discussion*—Tex is a unit of measure for the linear mass density of yarns and is defined as the mass in g/1000 m. Because of the low mass of yarns used in medical applications, decitex (abbreviated as dtex) is more commonly used, and is mass in g/10 000 m. Another related unit of measure for the linear mass density is denier, which is defined as g/9000 m.

¹ This specification is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.11 on Polymeric Materials.

Current edition approved June 1, 2010. Published July 2010. DOI: 10.1520/F2848-10.

² For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

³ Available from International Organization for Standardization (ISO), 1, ch. de la Voie-Creuse, Case postale 56, CH-1211, Geneva 20, Switzerland, <http://www.iso.ch>.

⁴ Available from International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), ICH Secretariat, c/o IFPMA, 15 ch. Louis-Dunant, P.O. Box 195, 1211 Geneva 20, Switzerland, <http://www.ich.org>.

3.1.4 *production liquid*—any liquid(s) used in the production of the filaments and yarns, such as solvents and extraction solutions.

4. UHMWPE Filament and Yarn Requirements

4.1 *Compositional Requirements:*

4.1.1 Current yarns used for medical application with clinical history are produced with decalin as solvent. The maximum decalin residual level is 100 mg/kg (see 6.1).

4.1.2 In case other production liquids are used, the acceptable residual levels of these particular production liquid(s) shall be reflective of toxicity, with a maximum acceptable limit consistent with ICH Q3C(R3). If no ICH concentration guideline has been established for a utilized production liquid, proof of biocompatibility has to be given.

4.1.3 To promote consistency in production and pureness of the yarn, concentration limits for trace elements have been established and are listed in Table 1.

4.2 *Physical Requirements:*

4.2.1 The density of the yarn shall comply with the requirement listed in Table 1.

4.2.2 The linear density requirement of single filaments is listed in Table 1.

4.2.3 The intrinsic viscosity requirement for the UHMWPE yarn is listed in Table 1.

4.3 *Mechanical Requirements:*

4.3.1 UHMWPE yarns shall meet the tensile requirements on strength, modulus and elongation-at-break as listed in Table 1. Note that tensile properties of the final medical device depend on the construction of yarns used therein.

4.4 *Biocompatibility Requirements:*

4.4.1 The UHMWPE yarn shall be biocompatible. While the biocompatibility of UHMWPE powder and fibers has been characterized (1-8),⁵ this data cannot be assumed to be appropriate for all uses of UHMWPE. When new applications of the material, or modification to the material or physical forms of the materials are being contemplated, biological testing shall be selected and conducted in accordance with Practice F748 or ISO 10993, depending on the available published biocompatibility data and the end-use application.

⁵ The boldface numbers in parentheses refer to a list of references at the end of this standard.

5. Sampling

5.1 Compliance with this specification shall be determined by sampling sizes and procedures as agreed upon between the purchaser and seller.

6. Test Methods

6.1 Residual production liquids shall be determined by gas chromatography or other suitable, validated analytical methods for the specific materials used to produce the yarn.

6.2 Determine the trace element concentrations of titanium, sodium, chromium, iron, and calcium by a validated analytical method, such as neutron activation analysis (NAA), inductively coupled plasma spectroscopy (ICP), atomic absorption (AA), or X-ray fluorescence (XRF).

6.3 Determine filament linear density by dividing the yarn linear density, measured according to Test Method D1907, by the number of filaments in the yarn.

6.4 The intrinsic viscosity shall be measured according to ISO 1628-3, but in the case of incomplete dissolution of the polymer, longer dissolution times and/or lower dissolution temperatures can be applied.

6.5 Determine tensile strength, tensile modulus and elongation-at-break as the average of 15 samples tested according to the following test conditions, derived from Test Methods D885, Test Method D2256, and ISO 2062, and optimized for UHMWPE yarns:

6.5.1 *Test Conditions:*

6.5.1.1 Temperature shall be $21 \pm 1^{\circ}\text{C}$, at a relative humidity between 40 and 75 %.

6.5.1.2 Twisting level shall be according to product specifications, and any change in twist shall be avoided.

6.5.1.3 Touching of the test specimen with bare hands shall be avoided.

6.5.1.4 Special care shall be taken to avoid slippage of the yarn in the clamps (see Appendix X2).

6.5.1.5 A load cell with an accuracy of at least $\pm 1\%$ at the anticipated breaking force of the yarn shall be used.

6.5.1.6 Gauge length shall be 500 mm.

6.5.1.7 A pre-tension (in Newton) of 0.2 % of the yarn linear density (in dtex) shall be applied at a speed of 50 mm/min to remove any slack from the yarn. The initial yarn length that is used in strain calculations, shall be adjusted

TABLE 1 Requirements for UHMWPE Yarns

Property	Test Method	Requirement
Trace Elements		
Titanium, mg/kg (Maximum)	6.2	25
Sodium, mg/kg (Maximum)	6.2	50
Chromium, mg/kg (Maximum)	6.2	10
Iron, mg/kg (Maximum)	6.2	100
Calcium, mg/kg (Maximum)	6.2	100
Density, g/cm ³	Test Methods D792	0.95–0.98
Filament Linear Density, dtex (Maximum)	6.3	2.7
Intrinsic Viscosity, dl/g (Minimum)	6.4	12.5
Tensile Strength, cN/dtex (Minimum)	6.5	28.0
Tensile Modulus, cN/dtex (Minimum)	6.5	750
Elongation-at-break, %	6.5	2.9–4.3

accordingly; that is, the value for the initial yarn length shall be the actual initial yarn length after pre-tensioning.

6.5.1.8 The extension rate shall be constant and half the gauge length per minute.

6.5.1.9 Force and elongation shall be recorded until yarn breakage.

6.5.2 For tensile strength (in cN/dtex), divide the maximum force-at-break (in cN) by the yarn linear density (in dtex) as determined according to Test Method **D1907**.

6.5.3 Tensile modulus (in cN/dtex) shall be determined as the slope of the regression line to the part of the force-elongation curve corresponding to strains between 0.3 % and

1.0 %, consisting of at least 45 data points. The slope (in cN) shall be divided by yarn linear density (in dtex) as determined by Test Method **D1907**.

6.5.4 Elongation-at-break (in %) shall be determined by dividing the increase in length after pre-tensioning until break, by the initial yarn length, and multiplying with 100 %.

7. Keywords

7.1 fiber; high-modulus polyethylene (HMPE); high-performance polyethylene (HPPE); medical; surgical implants; ultra-high molecular weight polyethylene (UHMW-PE, UHMWPE); yarn

APPENDIXES

(Nonmandatory Information)

X1. RATIONALE

X1.1 This specification is intended to describe the properties required and procedures to be followed in testing medical-grade UHMWPE yarns. This is different from Specification **F648**, which addresses UHMWPE powder and bulk shapes fabricated from this powder for surgical implants.

X1.2 While the biological response to medical-grade UHMWPE in soft tissue and bone has been well characterized by a history of clinical use (**1-3**) and by laboratory studies (**4-8**), the data cannot necessarily be assumed to be applicable to modified forms, including UHMWPE yarns, or applications of the material. The material user should carefully analyze the published biocompatibility data and then decide whether additional testing may be necessary as a result of the changes which may have been made.

X1.3 There is no evidence at this time that the concentration of trace elements has any effect on the physical properties or the biological response of UHMWPE fabricated forms. Limits for trace element concentrations in this standard are based on

experience with current medical-grade UHMWPE yarns.

X1.4 The relationship between these mechanical properties and the *in-vivo* performance of a fabricated form has not been determined. While trends are apparent, specific property-polymer structure relationships are not well understood. These mechanical tests are frequently used to evaluate the reproducibility of a fabrication procedure and are applicable as quality control tests to determine lot-to-lot repeatability for a process of converting virgin polymer powder into a fabricated form. The mechanical properties are subject to variation as the fabrication process variables (such as temperature, pressure and time) are changed.

X1.5 All properties are based on non-sterilized material, because this standard describes a raw material. The recommended method of sterilization is ethylene oxide sterilization. High-energy sterilization methods such as, for example, gamma-irradiation or e-beam irradiation are not advised since they may result in a loss of properties.

X2. SUGGESTED GUIDELINE FOR CLAMPING IN TENSILE TESTING

X2.1 This guideline is intended to minimize slip of the yarn in the clamps during tensile testing. It is recommended to use pneumatic yarn grips from the Instron type CP103684 with Instron 1498K stainless steel faces, especially designed to

overcome the problem of sample failure by incorporating a lever design which evenly distributes the gripping force over the surface.

REFERENCES

- (1) Charnley, J., Cupiz, A., “The Nine and Ten Year Results of the Low Friction Arthroplasty of the Hip,” *Clinical Orthopaedics*, Vol 95, No. 9, 1973.
- (2) Cimbrello, E. G., Munera, L., “Early and Late Loosening of the Acetabular Cup After Low-Friction Arthroplasty”, *The Journal of Bone and Joint Surgery*, Vol 74-A, No. 8, 1992.
- (3) Mirra, J., Amstutz, H., Matos, M., Gold, R., “The Pathology of the Joint Tissues and Its Clinical Relevance in Prosthesis Failure,” *Clinical Orthopaedics*, No. 117, 1976.
- (4) Turner, J., Lawrence, W., Autian, J., “Subacute Toxicity Testing of Biomaterials Using Histopathologic Evaluation of Rabbit Muscle Tissue,” *Journal of Biomedical Materials Research*, Vol 7, 1973.
- (5) Laing, P., “ Compatibility of Biomaterials,” *Orthopedic Clinics of North America*, Vol 4, No. 2, 1973.
- (6) Escalas, F., Galante, J., Rostoker, W., “Biocompatibility of Materials for Total Joint Replacement,” *Journal of Biomedical Materials Research*, Vol 10, No. 2, 1976.
- (7) Traoré, A. S., Guidoin, M. F., Marois, Y., Zhang, Z., Douville, Y., Guidoin, R., King, M. W., Legrand, A. P., “Newly developed hybrid suture with lubricant: noninvasive *in vivo* assessment of biocompatibility with multiparametric MR imaging,” *Journal of Investigative Surgery*, Vol 20, No. 2, 2007.
- (8) Kurtz, S. M., *The UHMWPE Biomaterials Handbook: Ultra-High Molecular Weight Polyethylene in Total Joint Replacement and Medical Devices (2nd edition)*. Burlington, MA: Academic Press, 2009.

ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.

This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.

This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or service@astm.org (e-mail); or through the ASTM website (www.astm.org). Permission rights to photocopy the standard may also be secured from the ASTM website (www.astm.org/COPYRIGHT/).